Endocrine and Metabolic Effects of Rosiglitazone in Non-obese Women with Polycystic Ovary Disease

1. Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333: 853-859.

2. Franks S, Gilling-Smith C, Watson H, Willis D (1999) Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 28: 361-378.

3. Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L (2002) Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care 25: 1217-1222.

4. Wild RA (2002) Long-term health consequences of PCOS. Hum Reprod Update 8: 231-241.

5. Azziz R (2002) Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 87: 4085-4087.

6. Kuscu NK, Koyuncu FM (2002) Insulin and oral antidiabetic agents for treatment of polycystic ovary syndrome. Medscape Womens Health 7: 3.

7. Iuorno MJ, Nestler JE (1999) The polycystic ovary syndrome: treatment with insulin sensitizing agents. Diabetes Obes Metab 1: 127-136.

8. Glueck CJ, Streicher P, Wang P (2002) Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 3: 1177-1189.

9. Kelestimur F, Unluhizarci K, Bayram F, Sahin Y, Tutus A (2000) Metformin and polycystic ovary syndrome. Clin Endocrinol (Oxf) 52: 244-246.

10. Costello MF, Eden JA (2003) A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79: 1-13.

11. Stadtmauer LA, Wong BC, Oehninger S (2002) Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-beyond ovulation induction. Hum Reprod 17: 3016-3026.

12. Awartani KA, Cheung AP (2002) Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 24: 393-401.

13. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 2108-2116.

14. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M (1995) Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80: 2057-2062.

15. Acbay O, Gundogdu S (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65: 946-949.

16. Sturrock ND, Lannon B, Fay TN (2002) Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 53: 469-473.

17. Day C (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16: 179-192.

18. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 3299-3306.

19. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 2108-2116.

20. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K (1999) Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 71: 323-327.

21. Mitwally MF, Kuscu NK, Yalcinkaya TM (1999) High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 14: 2700-2703.

22. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, and placebo-controlled trial. J Clin Endocrinol Metab 86: 1626-1632.

23. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD (2003) Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 576-580.

24. Wagstaff AJ, Goa KL (2002) Rosiglitazone: a review of its use in the management of type II diabetes mellitus. Drugs 62: 1805-1837.

25. Pi-Sunyer FX (2002) The medical risks of obesity. Obes Surg 12 Suppl 1: 6S-11S.

26. Steppan CM, Lazar MA (2002) Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13: 18-23.

27. Zawadzki JK, Dunaif (1992) A diagnostic criteria for polycystic ovary syndrome: towards a national approach. In: Dunaif A, Givens JR, Hasetline F, Merriam GR (eds) Polycystic Ovary Syndrome. Boston, Blackwell 377-384.

28. Azziz R, Dewailly D, Owerbach D (1994) Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 78: 810-815.

29. Peters AL (2000) Diagnosing diabetes in 2000. Curr Opin Endocrinol Diabetes 7: 31-37.

30. Matthews DR, Hosker JP, Rudenski A, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta cell function in man. Diabetologia 28: 401-411.

31. Hatch R, Rosenfield RL, Kim MH, Tredway D (1981) Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140: 815-830.

32. Nestler JE (1997) Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15: 111-122.

33. Dunaif A, Thomas A (2001) Current concepts in the polycystic ovary syndrome. Annu Rev Med 52: 401-419.

34. Ovalle F, Azziz R (2002) Insulin resistance, polycystic ovary syndrome, and type II diabetes mellitus. Fertil Steril 77: 1095-1105.

35. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type II diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169.

36. Arslanian SA, Lewy VD, Danadian K (2001) Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86: 66-71.

37. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A (2002) Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 1017-1023.

38. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141-146.

39. Stapley L (2001) PCOS and an increased risk of type II diabetes mellitus. Trends Endocrinol Metab 12: 146.

40. Rittmaster RS (1999) Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28: 409-421.

41. Ehrmann DA (1999) Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am 28: 423-438.

42. Bailey CJ (1993) Metformin - an update. Gen Pharmacol 24: 1299-1309.

43. Bailey CJ, Turner RC (1996) Metformin. N Engl J Med 334: 574-579.

44. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces Hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647-654.

45. Arslanian SA, Lewy V, Danadian K, Saad R (2002) Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87: 1555-1559.

46. Norman RJ, Davies MJ, Lord J, Moran LJ (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13: 251-257.

47. Hoeger K (2001) Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28: 85-97.

48. Nestler JE (2002) Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. Hum Reprod 17: 1950-1953.

49. Awartani KA, Cheung AP (2002) Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 24: 393-401.

50. Zheng Z, Li M, Lin Y, Ma Y (2002) Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 37: 271-273.

51. Arlt W, Auchus RJ, Miller WL (2001) Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 276: 167-171.

52. Mitwally MF, Witchel SF, Casper RF (2002) Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 9: 163-167.

53. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H (2000) Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 271: 710-713.